Viewing Study NCT00090311



Ignite Creation Date: 2024-05-05 @ 11:37 AM
Last Modification Date: 2024-10-26 @ 9:10 AM
Study NCT ID: NCT00090311
Status: COMPLETED
Last Update Posted: 2013-01-04
First Post: 2004-08-25

Brief Title: Quetiapine Fumarate SEROQUEL Compared to Placebo in the Treatment of Children Adolescents With Bipolar I Mania
Sponsor: AstraZeneca
Organization: AstraZeneca

Study Overview

Official Title: A 3-wk Multicenter Randomized Double-blind Parallel-group Placebo-controlled Phase 3b Study of the Efficacy Safety of Quetiapine Fumarate SEROQUEL Immediate-release Tablets in the Treatment of Children Adolescents With Bipolar I Mania Abbreviated
Status: COMPLETED
Status Verified Date: 2013-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ANCHOR 149
Brief Summary: The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate SEROQUEL compared with placebo in the treatment of children and adolescent patients with Bipolar I mania
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None